Cell transplant enables blind mice to see

Article

With hopes for helping humans to see, researchers announced promising results after transplanting photoreceptor precursor cells into mouse retinas.

 

Oxford, UK-A technique that may help restore vision in blind people was researched in a study using that stalwart lab assistant, the mouse. Once-blind mice can now see after receiving a retinal injection of light-sensitive cells-an approach that could one day help humans with disabling eye diseases.

“If we transplant cells in large enough numbers at the same developmental stage, these cells are able to interact with themselves and with the retinal environment to re-form the light-sensing layer,” said Robert MacLaren, the study’s lead author, and a professor of ophthalmology at the University of Oxford. MacLaren said that cells are transplanted through a very fine needle, describing how hundreds of thousands of cells are suspended in liquid between the two planes of the retina.

Using a mouse model of retinal degeneration, MacLaren and colleagues tested the effects of transplanted photoreceptor precursor cells-an intermediate between stem cells and the light-sensing cells of the adult eye. After 2 weeks, the transplanted cells had replaced the retina’s light-detecting layer, complete with connections to the optic nerve. A pupil constriction test found that 10 of the 12 mice showed an improved response to light, suggesting the once-blind mice could actually see-a finding bolstered by behavioral tests in which the mice, which are nocturnal, ran away from light. Before the transplant, they stayed put.

“Once we can address the safety issues, we can start clinical trials in patients,” MacLaren said. “If we can get to that stage, there is every potential that patients that are completely clinically blind will be able to see again.”

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.